Pharmacokinetic optimization of 4-substituted methoxybenzoylaryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability

Drug Metabolism and Disposition

Volumn 39, Issue 10, 2011, Pages 1833-1839

  Li, Chien Ming ^a   Chen, Jianjun ^b   Lu, Yan ^b   Narayanan, Ramesh ^a   Parke, Deanna N ^a   Li, Wei ^b   Ahn, Sunjoo ^a   Miller, Duane D ^a,b   Dalton, James T ^a  

^a GTx Inc   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARYL 4 BENZOYLIMIDAZOLE DERIVATIVE; 4 (3,4,5 TRIMETHOXYBENZOYL) 2 PHENYLTRIAZOLE; ABI 182; ABI 274; ABI 286; ANTINEOPLASTIC AGENT; ANTITUBULIN AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; BINDING SITES; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; COLCHICINE; DOGS; FEMALE; HUMANS; IMIDAZOLES; MALE; MICE; MICROSOMES, LIVER; MICROTUBULES; PACLITAXEL; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TUBULIN; TUBULIN MODULATORS; VINBLASTINE;

RATTUS; VINCA;

EID: 80053154666     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036616     Document Type: Article

References (26)

1. Baranczewski P, Stańczak A, Kautiainen A, Sandin P, and Edlund PO (2006) Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. Pharmacol Rep 58:341-352. (Pubitemid 44111069)
2. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, and Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333.
3. Chen J, Wang Z, Li CM, Lu Y, Vaddady PK, Meibohm B, Dalton JT, Miller DD, and Li W (2010) Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem 53:7414-7427.
4. Chiba M, Ishii Y, and Sugiyama Y (2009) Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11:262-276.
5. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, Sobel A, and Knossow M (2005) Structural basis for the regulation of tubulin by vinblastine. Nature 435:519-522. (Pubitemid 40734250)
6. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, et al. (2006) The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 12:2834-2840.
7. Humphrey MJ and Smith DA (1992) Role of metabolism and pharmacokinetic studies in the discovery of new drugs-present and future perspectives. Xenobiotica 22:743-755.
8. Jordan MA and Kamath K (2007) How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 7:730-742.
9. Jordan MA and Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265. (Pubitemid 38525281)
10. Lakhani NJ, Sarkar MA, Venitz J, and Figg WD (2003) 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23:165-172. (Pubitemid 36197457)
11. Li CM, Lu Y, Narayanan R, Miller DD, and Dalton JT (2010) Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazole (SMART). Drug Metab Dispos 38:2032-2039.
12. Li CM, Wang Z, Lu Y, Ahn S, Narayanan R, Kearbey JD, Parke DN, Li W, Miller DD, and Dalton JT (2011) Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor. Cancer Res 71:216-224.
13. Li HL, Zhang WD, Zhang C, Liu RH, Wang XW, Wang XL, Zhu JB, and Chen CL (2006) Bioavailability and pharmacokinetics of four active alkaloids of traditional Chinese medicine Yanhuanglian in rats following intravenous and oral administration. J Pharm Biomed Anal 41:1342-1346. (Pubitemid 43775908)
14. Liou JP, Hsu KS, Kuo CC, Chang CY, and Chang JY (2007) A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H- indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. J Pharmacol Exp Ther 323:398-405.
15. Lu Y, Li CM, Wang Z, Ross CR 2nd, Chen J, Dalton JT, Li W, and Miller DD (2009) Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J Med Chem 52:1701-1711.
16. Nogales E, Wolf SG, and Downing KH (1998) Structure of the alpha beta tubulin dimer by electron crystallography. Nature 391:199-203. (Pubitemid 28092482)
17. Palani A, Shapiro S, Josien H, Bara T, Clader JW, Greenlee WJ, Cox K, Strizki JM, and Baroudy BM (2002) Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. J Med Chem 45:3143-3160. (Pubitemid 34721536)
18. Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, Boxall J, Poupard L, Chaplin DJ, Stratford MR, et al. (2010) Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 102:1355-1360.
19. Sampath D, Discafani CM, Loganzo F, Beyer C, Liu H, Tan X, Musto S, Annable T, Gallagher P, Rios C, et al. (2003) MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther 2:873-884.
20. Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, and Discafani C (2006) Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models. Clin Cancer Res 12:3459-3469.
21. Stegemann S, Leveiller F, Franchi D, De Jong H, and Lindén H (2007) When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci 31:249-261. (Pubitemid 47079001)
22. Tahir SK, Nukkala MA, Zielinski Mozny NA, Credo RB, Warner RB, Li Q, Woods KW, Claiborne A, Gwaltney SL 2nd, Frost DJ, et al. (2003) Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative. Mol Cancer Ther 2:227-233.
23. Tan W, Chen H, Zhao J, Hu J, and Li Y (2008) A study of intestinal absorption of bicyclol in rats: active efflux transport and metabolism as causes of its poor bioavailability. J Pharm Pharm Sci 11:97-105.
24. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC, Blahy OM, and Roth E (1994) L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 91:4096-4100. (Pubitemid 24139580)
25. Wagner MM, Paul DC, Shih C, Jordan MA, Wilson L, and Williams DC (1999) In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother Pharmacol 43:115-125. (Pubitemid 29045028)
26. Watt AP, Mortishire-Smith RJ, Gerhard U, and Thomas SR (2003) Metabolite identification in drug discovery. Curr Opin Drug Discov Devel 6:57-65. (Pubitemid 36206940)